Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 3/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5848051 | 0.75 | HDAC4 (0.46) | CES2CES1 | |
| SCHEMBL7394160 | 0.74 | CES2 (0.41) | ACP3CES2CES1CYP2D6DPP4 | |
| SCHEMBL17956469 | 0.74 | TSHR (0.43) | SRCCES2CES1CYP2D6DPP4 | |
| SCHEMBL5042134 | 0.74 | ATM (0.42) | SRCCES2CES1CYP2D6DPP4 | |
| SCHEMBL773469 | 0.74 | CES2 (0.41) | ACP3CES2CES1CYP2D6DPP4 | |
| SCHEMBL4414048 | 0.73 | ACP3 (0.40) | ACP3SRCCES2CES1PTPN1 | |
| SCHEMBL10069117 | 0.72 | ESR1 (0.59) | ACP3SRCCYP2D6DPP4F2 | |
| SCHEMBL536997 | 0.72 | DPP4 (0.41) | ACP3SRCCYP2D6DPP4F2 | |
| SCHEMBL28837273 | 0.72 | SRC (0.39) | ACP3SRCCES2CES1PTPN1 | |
| SCHEMBL4274555 | 0.72 | SRC (0.39) | ACP3SRCCES2CES1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667638-B2 | 4-substitued cytisine analogues | THE UNIVERSITY OF BRISTOL | 2023-06-06 | — | — | US | claimed |
| EP-4112620-A1 | CYTISINE DERIVATIVES FOR THE TREATMENT OF ADDICTION | The University of Bristol (GB) | 2023-01-04 | — | — | EP | claimed |
| US-20200172544-A1 | COMPOUNDS | THE UNIVERSITY OF BRISTOL (GB) | 2020-06-04 | — | — | US | claimed |
| EP-3500572-A2 | CYTISINE DERIVATIVES FOR THE TREATMENT OF ADDICTION | The University Of Bristol (GB) | 2019-06-26 | — | — | EP | claimed |
| WO-2018033742-A2 | COMPOUNDS | THE UNIVERSITY OF BRISTOL (GB) | 2018-02-22 | — | — | WO | claimed |
| CN-101969773-B | compounds and methods for reducing uric acid | WELLSTAT THERAPEUTICS CORP. (US) | 2015-08-19 | — | — | CN | claimed |
| WO-2009080835-A1 | THYROMIMETRIC COMPOUNDS IN TREATMENT OF DISEASE RELATED TO SONIC HEDGEHOG SIGNALLING | KARO BIO AB (SE) | 2009-07-02 | — | — | WO | claimed |
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION (US) | 2005-06-23 | — | — | US | claimed |
| CN-1170827-C | Benzofurylpyrone derivatives | ������������ʽ���� | 2004-10-13 | — | — | CN | claimed |
| EP-1063235-B1 | BENZOFURYLPYRONE DERIVATIVES | TEIJIN LTD (JP) | 2004-05-12 | — | — | EP | claimed |
| JP-3187838-B2 | — | — | 2001-07-16 | — | — | JP | claimed |
| CN-1299359-A | Benzofurylpyrone derivatives | TEIJIN LTD (JP) | 2001-06-13 | — | — | CN | claimed |
| EP-1063235-A1 | BENZOFURYLPYRONE DERIVATIVES | TEIJIN LIMITED (JP) | 2000-12-27 | — | — | EP | claimed |
| EP-1047694-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-11-02 | — | — | EP | claimed |
| WO-1999035146-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-07-15 | — | — | WO | claimed |
| CN-1147254-A | Prodrugs of morpholine tachykinin receptor antagonists | MERCK & CO INC (US) | 1997-04-09 | — | — | CN | claimed |
| EP-0737195-A1 | NEW GINKGOLIDE DERIVATIVES AND A PROCESS FOR PREPARING THEM | SUNKYONG INDUSTRIES CO., LTD. (KR) | 1996-10-16 | — | — | EP | claimed |
| US-5541183-A | RESPIRATORY SYSTEM DISORDERS, SKIN DISORDERS AND PLATELET ACTIVATING FACTOR ANTAGONIST | SUNKYONG INDUSTRIES CO., LTD. (KR) | 1996-07-30 | — | — | US | claimed |
| WO-1995018131-A1 | NEW GINKGOLIDE DERIVATIVES AND A PROCESS FOR PREPARING THEM | SUNKYONG INDUSTRIES CO., LTD. (KR) | 1995-07-06 | — | — | WO | claimed |
| US-4009277-A | 1,2-Dialkyl-3,4,5-trisubstituted pyrazolium salts as fungicidal agents | AMERICAN CYANAMID COMPANY (US) | 1977-02-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | MAPKAPK2, MAP4K2, MAP3K2 | ACP3 3080/4885SRC 357/4885CES2 1928/4885 |
| US-11667638-B2 | 4-substitued cytisine analogues | CES2, CDA, PCYT1A | ACP3 4727/4885SRC 3124/4885CES2 1/4885 |
| US-20200172544-A1 | COMPOUNDS | CES2, CYCS, CHKB | ACP3 4509/4885SRC 2513/4885CES2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.